Get the Stockscreener App
0.00
100.00%
-4.84
Exscientia Plc Adr stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.
See More
Previous Close:
$4.84
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$633.18M
Revenue:
$25.81M
Net Income/Loss:
$-188.12M
P/E Ratio:
0.00
EPS:
-1.4747
Net Cash Flow:
$-183.77M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$6.875
Exscientia Plc Adr Stock (EXAI) Company Profile
Compare EXAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAI
Exscientia Plc Adr
|
0.00 | 633.18M | 25.81M | -188.12M | -183.77M | -1.4747 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Exscientia Plc Adr Stock (EXAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-24 | Initiated | TD Cowen | Buy |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
Exscientia Plc Adr Stock (EXAI) Latest News
Exscientia's SWOT analysis: ai biotech stock faces merger challenges - Investing.com India
Exscientia's SWOT analysis: ai biotech stock faces merger challenges By Investing.com - Investing.com South Africa
Exscientia's SWOT analysis: ai-driven biotech stock faces merger challenges - Investing.com
Exscientia and Recursion Merge to Revolutionize Drug Discovery - TipRanks
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition - Investing.com
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition By Investing.com - Investing.com UK
Recursion, Exscientia shareholders back merger - Investing.com
Such Is The Power Of Verizon Communications Inc (NYSE: VZ) - Stocks Register
Quarterly Metrics: Quick and Current Ratios for Exscientia Plc ADR (EXAI) - The Dwinnex
Exscientia advances two drug programs with Sanofi By Investing.com - Investing.com South Africa
Exscientia advances two drug programs with Sanofi - Investing.com
How to interpret Exscientia Plc ADR (EXAI)’s stock chart patterns - US Post News
Recursion’s All-Stock Acquisition of Exscientia plc (EXAI): NVIDIA-Backed Merger to Revolutionize AI-Driven Drug Discovery - Yahoo Finance
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? - MSN
Investing in Exscientia Plc ADR (EXAI) might be a great opportunity, but the stock is a bit undervalued - US Post News
Exscientia Plc ADR (EXAI)’s Market Momentum: Closing Strong at 5.06, Down -4.53 - The Dwinnex
Taking on analysts’ expectations and winning: Exscientia Plc ADR (EXAI) - SETE News
Exscientia's SWOT analysis: AI biotech stock faces merger, pipeline milestones - Investing.com
Exscientia Plc ADR (EXAI) expanding its growth trajectory ahead - SETE News
A stock that deserves closer examination: Exscientia Plc ADR (EXAI) - US Post News
Take off with Exscientia Plc ADR (EXAI): Get ready for trading - SETE News
Exscientia Plc ADR (EXAI)’s stock chart: A technical perspective - US Post News
Market Insights: Exscientia Plc ADR (EXAI)’s Notable Gain of 3.78, Closing at 5.22 - The Dwinnex
EXAI’s 52-Week Rollercoaster: From $3.80 to $7.91 – What’s Next for Investors? - The InvestChronicle
Recursion Pharmaceuticals secures key shareholder support - Investing.com
AI biotechs Exscientia and Recursion agree $688m merger - pharmaphorum
Amazon (AMZN) Plunges 19.1% in a Month: Should You Buy the Dip? - Yahoo Finance
Why Do Hedge Funds Think That Exscientia plc (EXAI) Will Skyrocket? - Yahoo Finance
Exscientia takes full control of cancer drug program - Investing.com
Amazon (AMZN) Expands AWS Clientele With Exscientia Deal - Yahoo Finance
How Much Upside is Left in Exscientia (EXAI)? Wall Street Analysts Think 61.43% - Yahoo Finance
Can Exscientia (EXAI) Climb 57.17% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Exscientia (EXAI) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
3 Small-Cap Stocks to Invest in AI Drug Development - TradingView
Exscientia Plc ADR (EXAI)’s financial ratios: A comprehensive overview - The Dwinnex
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
New Strong Buy Stocks for October 25th - Yahoo Finance
Sanofi-Aventis S.A. ADR (SNY-Q) QuotePress Release - The Globe and Mail
Exscientia (NASDAQ:EXAI) shareholders have endured a 55% loss from investing in the stock a year ago - Yahoo Finance
Exscientia Ltd ADR Stock Quote | Stock Price for EXAI - Financial Content
Exscientia (EXAI) Stock Price, News & Analysis - MarketBeat
NVIDIA Corporation (NVDA) Stock Price, News, Quote & History - Yahoo Finance
Exscientia Plc Adr Stock (EXAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
2.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):